Gotowa bibliografia na temat „Risque thrombotique”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Spis treści
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Risque thrombotique”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "Risque thrombotique"
Merdji, Hamid, Laurent Sattler, Sibylle Cunat, Ferhat Meziani i Julie Helms. "Hémostase et COVID-19". Médecine Intensive Réanimation 30, Hors-série 1 (16.06.2021): 35–42. http://dx.doi.org/10.37051/mir-00062.
Pełny tekst źródłaCasadevall, N., i M. M. Samama. "Risque thrombotique des syndromes myéloprolifératifs". Journal des Maladies Vasculaires 33 (marzec 2008): S27—S28. http://dx.doi.org/10.1016/j.jmv.2008.01.091.
Pełny tekst źródłaCatteau-Jonard, S. "Risque thrombotique des nouvelles contraceptions". Journal des Maladies Vasculaires 36, nr 5 (wrzesień 2011): 306–7. http://dx.doi.org/10.1016/j.jmv.2011.07.059.
Pełny tekst źródłaÉmile, Carole. "Risque thrombotique de la Covid-19". Option/Bio 32, nr 629-630 (marzec 2021): 20–21. http://dx.doi.org/10.1016/s0992-5945(21)00048-9.
Pełny tekst źródłaTrillot, N., V. Tintillier, B. Jude, C. Biron-Andréani, P. E. Morange i S. Susen. "Risque thrombotique veineux de la femme jeune". Journal des Maladies Vasculaires 40, nr 2 (marzec 2015): 77–78. http://dx.doi.org/10.1016/j.jmv.2014.12.077.
Pełny tekst źródłaAiach, Martine. "Risque thrombotique veineux, grossesse et traitement ȩstroprogestatif". Revue Française des Laboratoires 2003, nr 349 (styczeń 2003): 11–13. http://dx.doi.org/10.1016/s0338-9898(03)80043-4.
Pełny tekst źródłaBelizna, C., i A. Ghali. "Titres des anticorps anticardiolipine et risque thrombotique". La Revue de Médecine Interne 35 (czerwiec 2014): A60. http://dx.doi.org/10.1016/j.revmed.2014.03.067.
Pełny tekst źródłaGodier, Anne, i Sophie Susen. "Risque thrombotique des traitements médicamenteux des hémorragies". Anesthésie & Réanimation 1, nr 3 (czerwiec 2015): 248–55. http://dx.doi.org/10.1016/j.anrea.2014.12.013.
Pełny tekst źródłaGuy, Alexandre, i Chloé James. "La thrombose au cours des néoplasies myéloprolifératives". médecine/sciences 35, nr 8-9 (sierpień 2019): 651–58. http://dx.doi.org/10.1051/medsci/2019133.
Pełny tekst źródłaKeïta-Meyer, H. "Risque thrombotique dans le postpartum : facteurs de risque généraux et obstétricaux". Journal des Maladies Vasculaires 37, nr 2 (marzec 2012): 48–49. http://dx.doi.org/10.1016/j.jmv.2011.12.088.
Pełny tekst źródłaRozprawy doktorskie na temat "Risque thrombotique"
Collet, Jean-Philippe. "Anomalie qualitative du fibrinogène, facteur de risque thrombotique ?" Rouen, 1996. http://www.theses.fr/1996ROUE03NR.
Pełny tekst źródłaJesel-Morel, Laurence. "Sénescence, remodelage tissulaire et membranaire, risque thrombotique au cours de la fibrillation auriculaire". Thesis, Strasbourg, 2016. http://www.theses.fr/2016STRAJ051/document.
Pełny tekst źródłaOur data evidence that during atrial fibrillation (AF), microparticles (MP) contribute to an enhanced hypercoagulable and pro-inflammatory state. Similar concentrations of MP measured in left and right atria of AF patients highlight the absence of chamber-specific enhanced thrombogenic status. During AF ablation procedures, MP concentrations progress in parallel with cell and platelet activation. We also showed that AF progression is strongly related to human atrial senescence burden pointing toward a possible network that links in human atrium, senescence burden, endothelial dysfunction, thrombogenicity and atrial remodeling. We also developed a model of left atrium endothelial cell replicative senescence providing compelling evidences indicating that atrial endothelial senescence promotes thrombogenicity, inflammation and proteolysis. These data underline the major role of renin-angiotensin system in endothelial atrial cell senescence
Bene, Johana. "Déterminants du risque hémorragique et thrombotique des anticoagulants oraux et études de bon usage". Thesis, Lille 2, 2016. http://www.theses.fr/2016LIL2S012/document.
Pełny tekst źródłaFor over six decades, vitamin K antagonists (VKAs) were the only class of oral anticoagulants available on the market. The arrival of Direct Oral Anticoagulants (DOAs) in 2008 marked a real turning point in the oral anticoagulation. The first part of this work was interested in the characteristics of patients treated with anticoagulants and the consequences in terms of hospitalizations for ischemic or hemorrhagic events. In a cohort of patients hospitalized for stroke (cohort BIOSTROKE Lille), no particular influencer, on the onset and course (mortality, cognitive decline, and disability at 3 months) of stroke was highlighted. In parallel, a study conducted in the emergency department of the Hospital of Bethune on three years (2012, 2014, 2016) to observe oral anticoagulants prescriptions and the impact of DOAs arriving, showed a population where many characteristics appear to be associated with a more readily using DOAs or VKAs. The number of bleeding and thrombotic events with VKAs remained stable during the three study periods (in total 770 patients were included). With these reassuring data, the second part of this work has focused on prescribing practices and the appropriate use of anticoagulants, with a particular focus on DOAs, through three studies: one conducted among general practitioners of Nord and Pas de Calais departments, which showed a rather wary about DOAs but with a preference for anti-Xa. The other two studies focused on the appropriate use of DOAs, estimated from pharmacy (with the participation of pharmacy students of the Faculty of Lille) and hospital (Lille Regional Hospital Center) prescriptions. Data about DOAs prescriptions were transposable to French data, albeit with city / hospital disparities. Non-appropriate prescriptions were observed in less than one-third file, with a high proportion of under dosing situations. In conclusion, this work has allowed updating training tracks / information for health care professionals on these new anticoagulant molecules to improve information and optimal patients’ care
Le, Flem Léna. "Etude du promoteur du gène de la thrombomoduline dans la maladie thrombotique veineuse". Paris 5, 1997. http://www.theses.fr/1997PA05P031.
Pełny tekst źródłaZuily, Stéphane. "Proposition de nouveaux critères cliniques et biologiques dans l'évaluation du risque thrombotique des patients atteints de syndrome des antiphospholipides". Thesis, Université de Lorraine, 2014. http://www.theses.fr/2014LORR0064.
Pełny tekst źródłaAntiphospholipid syndrome (APS) is characterized by an auto-immune disorder with thrombotic and obstetrical morbidity in the presence of persistant antiphospholipid antibodies (aPL). This work studied clinical manifestations and laboratory assays for the determination of thrombotic risk in APS patients. Firstly, the risk of heart valve disease associated with aPL in systemic lupus erythematosus (SLE) patients was studied. Since 20 years, data regarding this association yielded conflicting results. A systematic review and a meta-analysis were performed to compare frequencies of heart valve disease in SLE patients with and without aPL. Main result concluded that the presence of aPL in SLE patients is associated with a 3-fold increased risk for heart valve disease in comparison with SLE patients without these antibodies. Secondly, prognostic significance of superficial vein thrombosis (SVT) was studied in APS patients. A prospective cohort study was performed and showed that SVT was predictive of thrombotic events overtime in this population. Moreover, the contribution of new laboratory assays were studied (antibodies directed against the domain I of [beta]2-Glycoprotein I and thrombin generation assay assessing sensitivity to activated protein C). Results demonstrated that these two assays were predictive of thrombotic events in APS patients. Finally, health-related quality of life was assessed in a multicentric cohort study of patients with aPL and/or SLE. Results showed that the presence of a history of arterial thrombosis was significantly associated with an impairment of all dimensions scores assessed by the MOS-SF36 questionnaire in comparison with patients with an auto-immune disease but without arterial thrombosis. This work provides new insights in the field of APS and may have an impact in the evolution leading to new classification criteria for definite APS
Aubert, Hélène. "Mise en évidence du déterminisme génétique du taux plasmatique de TAFI : Etude de la contribution du TAFI au risque thrombotique artériel". Aix-Marseille 2, 2003. http://www.theses.fr/2003AIX22063.
Pełny tekst źródłaLabbé, Vincent. "Risques thrombotiques et hémodynamiques chez les patients hospitalisés en réanimation présentant une fibrillation atriale de novo au cours d’un sepsis : caractérisation, stratification et stratégies thérapeutiques". Electronic Thesis or Diss., Sorbonne université, 2023. https://accesdistant.sorbonne-universite.fr/login?url=https://theses-intra.sorbonne-universite.fr/2023SORUS556.pdf.
Pełny tekst źródłaObjectives Patients admitted to intensive care units with sepsis are at high risk of thrombotic events (TEs) throughout the circulatory systems (systemic, coronary, and pulmonary). We aimed to investigate the thrombotic risk during sepsis (i) within the systemic circulation in patients with new-onset atrial fibrillation (NOAF), (ii) within the coronary circulation in patients with acute myocardial infarction (MI), and (iii) within the pulmonary circulation in patients with severe COVID-19. Furthermore, while the risk of TE raises the question of whether thromboprophylaxis doses should be escalated, assessment of associated bleeding risk should be systematic in order to establish the benefit/risk balance of such treatment. Methods We investigated the risk of major cardiovascular events (risk characterization and stratification), including AT, major bleeding and death in three populations of septic patients with NOAF, MI or severe COVID-19 by studying (i) markers such as left atrial dysfunction on transesophageal echocardiography (TEE) and cardiac troponin, and (ii) thrombotic and hemorrhagic risk scores used in cardiology patients. We conducted a practice survey on thrombotic risk management in patients with de NOAF during sepsis. Finally, we carried out two therapeutic trials: the CAFS (Control Atrial Fibrillation Sepsis) multicenter, randomized, controlled superiority trial comparing three usual strategies to prevent hemodynamic risk with NOAF during septic shock (currently being included), and the ANTICOVID (ANTIcoagulation in patients with hypoxemic COVID-19 pneumonia) multicenter, randomized, controlled superiority trial comparing three anticoagulation strategies with dose escalation in patients with hypoxemic COVID-19 pneumonia Results Our work confirmed the high risk of major cardiovascular events during sepsis. In patients with NOAF, cardiological approaches to thrombotic (TEE abnormalities, CHA2DS2-VASc score) and hemorrhagic (HAS-BLED score) risk stratification seem limited. An individualized approach with TEE based on the CHA2DS2-VASc score could nevertheless be of interest. This work also better characterized the risk of intra-cardiac thrombus formation (absence of thrombus within 48 h of AF onset, low prevalence of post-cardioversion left atrial stunning). Finally, we confirmed the heterogeneity of hemodynamic and thrombotic risks management, calling for randomized trials. In patients with MI during sepsis, cardiological approaches to thrombotic risk stratification (GRACE and TIMI scores) also appear limited. In usual practice, an invasive strategy involving early coronary revascularization is very uncommon. In patients investigated using coronary angiography, the incidence of obstructive coronary artery disease is high. In patients with hypoxemic COVID-19 pneumonia, high-dose prophylactic anticoagulation, provided a better net clinical benefit driven by a 4-fold reduction in de novo thrombosis rate with no increase in major bleeding compared with standard-dose prophylactic anticoagulation. Also, therapeutic anticoagulation did not provide additional benefit in comparison with high-dose prophylactic anticoagulation. Conclusions On the basis of the common pro-thrombotic pathophysiology described in septic conditions, our work has made it possible to (i) better characterize clinical situations at particularly high thrombotic risk (NOAF, MI, severe COVID-19 infection), (ii) develop individual therapeutic strategies for thrombotic risk prevention (COVID-19), and (iii) establish the basis for subsequent trials in specific intensive care populations at very high thrombotic risk
Chauleur, Céline. "Identification des facteurs de risque pour prévenir les complications thrombotiques et hémorragiques de la grossesse". Saint-Etienne, 2009. http://www.theses.fr/2009STET003T.
Pełny tekst źródłaCzęści książek na temat "Risque thrombotique"
Odent, T., B. de Courtivron i Y. Gruel. "Risque thrombotique et chirurgie orthopédique chez l'enfant". W Conférences D'enseignement 2019, 155–62. Elsevier, 2019. http://dx.doi.org/10.1016/b978-2-294-76675-6.00014-7.
Pełny tekst źródła